Regent Pacific's Commercial Strategic Partner Receives Approval from Taiwan Food and Drug Administration
December 14, 2020 at 05:50 pm IST
Share
Regent Pacific Group Limited announced that Orient EuroPharma Co. Ltd. the Group's commercial strategic partner for Taiwan, Hong Kong, Macau and some other countries and regions in South East Asia has received the marketing authorisation approval for Taiwan from the Taiwan Food and Drug Administration. This is the final regulatory approval process required for the marketing, distribution and sale of Fortacin, a solution to premature ejaculation, in Taiwan. Pursuant to the licence agreement with Orient EuroPharma, Regent Pacific will receive a payment of $300,000 from Orient EuroPharma.
Orient Europharma Co., Ltd. is principally engaged in the manufacture and distribution of nutritious healthcare products and medical cosmetic products, as well as western drugs. The Company operates nutritious healthcare products and medical cosmetic products segment, providing infant milk powders, nutritious products and functional healthcare products, as well as dermatological preparations, medical hair care series, organic skin care series and medical make-up products, among others; western drugs segment, providing products for cardiovascular diseases, cancer, blood diseases, diabetes, central nervous system diseases and asthma, among others.